A Study of MRX2843 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

Phase 1/2 Unknown 104 enrolled Betta Pharmaceuticals Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

Patients will receive oral MRX2843 for 28 days to study the side effects, tolerability and best dose for treating relapsed or refractory acute myeloid leukemia With FLT3 Mutations.

Timeline

Start: 2021-07-01
Primary completion: 2024-12-31
Completion: 2024-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MRX-2843	Unknown	80 mg	Oral
Subject	MRX-2843	Unknown	120 mg	Oral
Subject	MRX-2843	Unknown	180 mg	Oral

A Study of MRX2843 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

Summary

Timeline

Drugs

Indications